Hemic & Lymphatic

DC 7718

Essential thrombocythemia and primary myelofibrosis

Educational use only. Not legal or medical advice. Read 38 CFR §4.117 on eCFR
Diagnostic Code
7718
CFR Section
§4.117 — Hemic & Lymphatic

Rating Tiers

100%

Requiring either continuous myelosuppressive therapy, or, for six months following hospital admission for any of the following treatments: peripheral blood or bone marrow stem cell transplant, or chemotherapy, or interferon treatment

70%

Requiring continuous or intermittent myelosuppressive therapy, or chemotherapy, or interferon treatment to maintain platelet count <500 × 10/L[9]

30%

Requiring continuous or intermittent myelosuppressive therapy, or chemotherapy, or interferon treatment to maintain platelet count of 200,000-400,000, or white blood cell (WBC) count of 4,000-10,000

What Raters Look For

Based on M21-1 adjudication criteria for Hemic & Lymphatic conditions. These are the factors a VA rater evaluates when assigning a rating percentage.

M21-1 III.iv.4.G
  • •Complete blood count (CBC) values: hemoglobin, platelet count, white cell count
  • •Whether transfusions are required and how frequently
  • •Bone marrow biopsy or transplant history
  • •Response to treatment and current treatment regimen
  • •Constitutional symptoms: fatigue, weight loss, fever